Media Centre
Latest press releases
-
Vaxzevria approved in the EU as third dose booster against COVID-19
-
AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
-
AstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies against COVID-19
-
PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation compared to albuterol by 27% in patients with asthma
-
Human ventricular progenitor cells promote the formation of new heart tissue following a heart attack
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 (0)1223 344 800
Amanda Talamonte
Manager, Global Media Relations
+44 (0)1223 344 800
Angela Fiorin
Director, Global Media Relations (Oncology)
+44 (0)1223 344 800
Brendan McEvoy
Head, US External Communications
+1 302 885 2677
Fiona Cookson
Director, Global Media Relations
(COVID-19 and BioPharmaceuticals)
+44 (0)1223 344 800
Flavia Garcia
Manager, Global Media Relations
+44 (0)1223 344 800
Freja Annamatz
Director, Media Relations, Sweden
freja.annamatz@astrazeneca.com
+46 722 084 748
Kim Blomley
Director, Global Media Relations (Corporate)
+44 (0)1223 344 800
Lisa Taylor
Senior Director, Corporate Communications (Alexion)
+1 857 338 9025
Sinead Keller
Director, Global Media Relations
(COVID-19 and BioPharmaceuticals)
+44 (0)1223 344 800
